To evaluate the effectiveness of NanoBE engagement, we first conducted the separated studies on the specific binding of Nano/CLDN18.2 with tumor cells and the macrophage activation induced by Nano/CD40, respectively. This evidence concerns the gene CD40 and neoplasm.